Aim 100 

The Aim 100 2020: 20 to 11

The Aim 100 2020: 20 to 11

20. Clinigen

Clinigen (CLIN) has only faced marginal disruption from Covid-19 – something it attributes to the strength of its diversified operations and its partners in the healthcare industry. The pharmaceuticals group said in mid-April that trading for the year to June continued to be in line with management’s expectations and that it had enjoyed a strong first nine months of the year – with organic gross profits up by more than a tenth to the end of March.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now